Aytu BioScience, Inc.(AYTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AYTU Aytu BioScience, Inc.

Trading 05-18 12:08:36 EDT

2.12

-0.07

-3.42%

High2.19	Low2.11	Vol31.40K
Open2.19	D1 Closing2.19	Amplitude3.65%
Mkt Cap22.70M	Tradable Cap12.04M	Total Shares10.73M
T/O67.70K	T/O Rate0.55%	Tradable Shares5.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AYTU","market":"US","secType":"STK","nameCN":"Aytu BioScience, Inc.","latestPrice":2.115,"timestamp":1779120162061,"preClose":2.19,"halted":0,"volume":31395,"delay":0,"changeRate":-0.034246575342465634,"floatShares":5694400,"shares":10733200,"eps":-3.388,"marketStatus":"Trading","change":-0.075,"latestTime":"05-18 12:08:36 EDT","open":2.19,"high":2.19,"low":2.11,"amount":67703.844936,"amplitude":0.03653,"askPrice":2.12,"askSize":1941,"bidPrice":2.11,"bidSize":124,"shortable":3,"etf":0,"ttmEps":-3.388,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.19,"preHourTrading":{"tag":"盘前","latestPrice":2.21,"preClose":2.19,"latestTime":"07:00 EDT","volume":10,"amount":22.1,"timestamp":1779102005916,"change":0.02,"changeRate":0.009132,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.19,"preClose":2.19,"latestTime":"17:11 EDT","volume":37,"amount":82.23,"timestamp":1778879508787,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.825017,"impliedVol":2.5831,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AYTU","defaultTab":"news","newsList":[{"id":"2635748952","title":"Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748952?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:21","pubTimestamp":1778764882,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Assertio Therapeutics (ASRT), Aytu BioScience (AYTU) and Oruka Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assertio-therapeutics-asrt-aytu-bioscience-aytu-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assertio-therapeutics-asrt-aytu-bioscience-aytu-and-oruka-therapeutics-orka-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4007","XLV","HCSG","BK4139","AYTU","BK4585","XBI","LU0128526141.USD","LABU","ASRT","BK4137","BK4588","BK4581","ORKA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754888","title":"Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754888","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635754888?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:39","pubTimestamp":1778711993,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings SummaryAytu Biopharma Inc AYTU.OQ reported a quarterly adjusted loss of 53 cents per share for the quarter ended March 31, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q30J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759760","title":"Aytu Biopharma posts corporate presentation highlighting CNS portfolio, including EXXUA for depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759760","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759760?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:42","pubTimestamp":1778708579,"startTime":"0","endTime":"0","summary":"Aytu Biopharma highlighted commercial focus on complex CNS conditions, centered on major depressive disorder and ADHD.Presentation positioned EXXUA  extended-release tablets as a first-in-class MDD treatment, citing efficacy from two eight-week, randomized, placebo-controlled trials.Orange Book patent protection cited through late 2030, with Hatch-Waxman new chemical entity exclusivity through 9/28.Launch update showed EXXUA total prescriptions rising to 1,912 in Apr-26 from 546 in Dec-25, with shipments increasing to 920 from 43 over same period.Aytu RxConnect patient access program described as covering more than 1,000 pharmacies nationwide, aimed at improving access, adherence, and prescription pull-through across portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL12DbkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635537757","title":"Aytu BioPharma Q3 revenue falls amid EXXUA launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2635537757","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635537757?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:25","pubTimestamp":1778703928,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Q3 revenue falls amid EXXUA launchOverviewU.S. CNS drugmaker's fiscal Q3 revenue fell yr/yr but beat analyst expectationsAdjusted EBITDA swung to a loss for fiscal Q3 but beat analyst e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q161:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717758","title":"Aytu Biopharma FY26 Q3 turns to $5.6 million net loss; revenue drops to $12.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717758","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:08","pubTimestamp":1778702905,"startTime":"0","endTime":"0","summary":"Aytu BioPharma posted Q3 fiscal 2026 net loss of $5.6 million, swinging from net income of $4 million a year earlier, as net revenue fell 32.73% to $12.4 million.Adjusted EBITDA turned to a loss of $2.8 million from a profit of $3.9 million, reflecting planned EXXUA launch investments.EXXUA contributed $2.4 million in net revenue, with more than 1,300 prescriptions written by more than 450 unique prescribers during the quarter.Cash and cash equivalents totaled $26.7 million at March 31, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbJHvx3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758789","title":"Aytu BioPharma Q3 EPS $(0.53) Misses $(0.51) Estimate, Sales $12.411M Beat $12.053M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758789","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758789?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:07","pubTimestamp":1778702854,"startTime":"0","endTime":"0","summary":"Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.51) by 3.92 percent. This is a 352.38 percent decrease over earnings of $0.21 per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52543089/aytu-biopharma-q3-eps-0-53-misses-0-51-estimate-sales-12-411m-beat-12-053m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aytu BioPharma Q3 EPS $(0.53) Misses $(0.51) Estimate, Sales $12.411M Beat $12.053M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758459","title":"Aytu Biopharma Q3 Adjusted Ebitda USD -2.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758459?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXACE167:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AYTU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635000172","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2635000172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635000172?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:00","pubTimestamp":1778666400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Copa Hldgs A                                     1Q      4.14    4:30 PM. ·FLEX LNG Ltd                                    1Q       .36    1:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","BGSI","CSCO","BN","PHVS","AEBI","ALLO","CMPS","BIRK","BABA","CLPT","BEEM","CCCC","CAAP","CPA","CLBT","CSWC","BBWI","AQST","ATS","BTDR","CNTB","BOOT","BEAT","AKA","BTGO","CLNN","GOOS","ATAT","AUTL","BZAI","AYTU","CING","DERM","CBUS","KARO","PYPD","BTBT","BLSH","CCAP","ABEO","ARX","ALT","CELC","AMAT","AVAH","CSIQ","BWAY","ATYR","BHST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634538902","title":"Aytu Biopharma Inc  expected to post a loss of 51 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634538902","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634538902?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:12","pubTimestamp":1778533926,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Inc  expected to post a loss of51cents a share - Earnings Preview Aytu Biopharma Inc AYTU.OQ AYTU.O is expected to  show a fall in quarterly revenue when it reports  results on May 13 f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2MH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633409151","title":"Aytu BioPharma to report fiscal Q3 results, host conference call after market close","url":"https://stock-news.laohu8.com/highlight/detail?id=2633409151","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633409151?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:08","pubTimestamp":1778098101,"startTime":"0","endTime":"0","summary":"Aytu BioPharma will report fiscal 2026 third-quarter operational and financial results May 13, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL95w1tY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624663516","title":"Aytu Biopharma presentation spotlights EXXUA launch for major depressive disorder growth strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2624663516","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624663516?lang=en_us&edition=fundamental","pubTime":"2026-04-04 00:34","pubTimestamp":1775234067,"startTime":"0","endTime":"0","summary":"Aytu Biopharma highlighted strategic realignment toward profitable prescription pharmaceuticals focused on central nervous system conditions, with June 30 fiscal year-end reporting.Adjusted EBITDA improved by USD 34.7 million over a four-year period.Net revenue totaled USD 57.8 million in fiscal 2021, compared with USD 42.9 million in fiscal 2025.EXXUA, a once-daily extended-release gepirone tablet for major depressive disorder in adults, was positioned as a key growth driver for portfolio revenue.EXXUA patent protection was described as extending through late 2030, with new chemical entity exclusivity through 9/28.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL79PW5T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624316682","title":"Aytu Biopharma issues amended warrants in unregistered exchange to restore equity classification","url":"https://stock-news.laohu8.com/highlight/detail?id=2624316682","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624316682?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:12","pubTimestamp":1775160767,"startTime":"0","endTime":"0","summary":"Aytu Biopharma amended warrants issued in June 2023 and June 2025, canceling prior instruments and issuing amended prefunded warrants and a Tranche A warrant to institutional investors on March 31, 2026.Transaction was structured as an unregistered exchange of securities, relying on Securities Act exemptions including Section 3 and Section 4.Warrant terms were revised to clarify stockholders cannot vote to amend beneficial ownership blockers, addressing accounting ambiguity that had driven liability classification.Company expects warrant liability on financial statements to decline, with a corresponding increase in equity value.Warrant liability recorded was USD 18.1 million for quarter ended Sept. 30, 2025, rising to USD 25.2 million for quarter ended Dec. 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLD99XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620405578","title":"Aytu Biopharma publishes investor presentation on its CNS-focused prescription portfolio and EXXUA for major depressive disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405578","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405578?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:09","pubTimestamp":1773781780,"startTime":"0","endTime":"0","summary":"Aytu Biopharma publishes investor presentation on its CNS-focused prescription portfolio and EXXUA for major depressive disorder. Aytu said it is focused on prescription pharmaceuticals for central nervous system conditions, including major depressive disorder and attention deficit hyperactivity disorder. The presentation lists key actions including the suspension of clinical development programs and the wind down and divestiture of its consumer health business. Aytu reported adjusted EBITDA of USD 9.2 million for fiscal 2025. It also reported net revenue of USD 42.9 million for fiscal 2025. Aytu said it launched EXXUA, an FDA-approved once-daily extended-release gepirone tablet for major depressive disorder in adults.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL5Z43kg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609036643","title":"Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Aytu BioScience (AYTU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609036643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609036643?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:20","pubTimestamp":1770297604,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bio-Techne (TECH – Research Report) and Aytu BioScience (AYTU – R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bio-techne-tech-and-aytu-bioscience-aytu-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bio-techne-tech-and-aytu-bioscience-aytu-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","LU0029874061.USD","IE00B19Z6F94.USD","IE0034390439.USD","AYTU","BK4588","TECH","XLV","BK4137","LU0128526141.USD","LABU","XBI","BK4121","IE00B64QTZ34.USD","BK4007","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609130805","title":"Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2609130805","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609130805?lang=en_us&edition=fundamental","pubTime":"2026-02-05 18:44","pubTimestamp":1770288281,"startTime":"0","endTime":"0","summary":"Insiders who bought Aytu BioPharma, Inc. ( NASDAQ:AYTU ) in the last 12 months may probably not pay attention to the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aytu/aytu-biopharma/news/aytu-biopharma-insider-buyers-net-us87k-despite-10-stock-dec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aytu/aytu-biopharma/news/aytu-biopharma-insider-buyers-net-us87k-despite-10-stock-dec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608670389","title":"Aytu Biopharma stellt neue Unternehmenspräsentation mit Fokus auf Therapien für Depression und ADHS vor","url":"https://stock-news.laohu8.com/highlight/detail?id=2608670389","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608670389?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:07","pubTimestamp":1770160023,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Inc. hat eine neue Prsentation verffentlicht, in der aktuelle Entwicklungen und strategische Manahmen des Unternehmens vorgestellt werden. Zu den jüngsten Ereignissen zhlen die Refinanzierung eines Terminkredits, die Auslagerung der Produktion an einen US-amerikanischen Drittanbieter, die Veruerung des Consumer-Health-Geschfts sowie der exklusive Vertriebsstart des Medikaments EXXUA in den USA. Zudem werden Kennzahlen zur Umsatzentwicklung und zur finanziellen Performance prsentiert. Die vollstndige Prsentation knnen Sie über den untenstehenden Link abrufen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief on February 03, 2026, and is solel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL5gHrNZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608638826","title":"Aytu BioPharma Q2 revenue beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2608638826","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608638826?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:21","pubTimestamp":1770153700,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Q2 revenue beats expectationsOverviewPharmaceutical company's Q2 revenue beat analyst expectationsAdjusted EBITDA for Q2 beat analyst expectationsOutlookCompany did not provide specific","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nL1N3YZ1BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608380043","title":"Aytu BioPharma Q2 EPS $(1.05) Misses $(0.49) Estimate, Sales $15.165M Beat $12.174M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2608380043","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608380043?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:07","pubTimestamp":1770152849,"startTime":"0","endTime":"0","summary":"Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.49) by 112.98 percent. This is a 275 percent decrease over losses of $(0.28) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50353269/aytu-biopharma-q2-eps-1-05-misses-0-49-estimate-sales-15-165m-beat-12-174m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aytu BioPharma Q2 EPS $(1.05) Misses $(0.49) Estimate, Sales $15.165M Beat $12.174M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608001218","title":"Aytu Biopharma meldet für das zweite Quartal (Q2) 2026 einen Nettoverlust von USD 10,58 Mio. und einen Rückgang des bereinigten EBITDA um 163 Prozent auf USD -0,80 Mio","url":"https://stock-news.laohu8.com/highlight/detail?id=2608001218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608001218?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:06","pubTimestamp":1770152800,"startTime":"0","endTime":"0","summary":"Aytu Biopharma meldet für das zweite Quartal  2026 einen Nettoverlust von USD 10,58 Mio. und einen Rückgang des bereinigten EBITDA um 163 Prozent auf USD -0,80 Mio. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL90Y5pt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608380096","title":"Aytu Biopharma Q2 Gross Profit USD 9.624 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608380096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608380096?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:05","pubTimestamp":1770152702,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nPLXC886D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AYTU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aytubio.com","stockEarnings":[{"period":"1week","weight":-0.124},{"period":"1month","weight":-0.1544},{"period":"3month","weight":0.0282},{"period":"6month","weight":0.0478},{"period":"1year","weight":-0.1544},{"period":"ytd","weight":-0.1577}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":0.044601},{"month":2,"riseRate":0.2,"avgChangeRate":-0.150336},{"month":3,"riseRate":0.4,"avgChangeRate":0.18333},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.0486},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.106692},{"month":6,"riseRate":0.375,"avgChangeRate":0.032109},{"month":7,"riseRate":0.375,"avgChangeRate":-0.022822},{"month":8,"riseRate":0,"avgChangeRate":-0.185643},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.05021},{"month":10,"riseRate":0.333333,"avgChangeRate":0.212856},{"month":11,"riseRate":0.111111,"avgChangeRate":-0.084654},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.055628}],"exchange":"NASDAQ","name":"Aytu BioScience, Inc.","nameEN":"Aytu BioScience, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aytu BioScience, Inc.(AYTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aytu BioScience, Inc.(AYTU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aytu BioScience, Inc.,AYTU,Aytu BioScience, Inc.股票,Aytu BioScience, Inc.股票老虎,Aytu BioScience, Inc.股票老虎国际,Aytu BioScience, Inc.行情,Aytu BioScience, Inc.股票行情,Aytu BioScience, Inc.股价,Aytu BioScience, Inc.股市,Aytu BioScience, Inc.股票价格,Aytu BioScience, Inc.股票交易,Aytu BioScience, Inc.股票购买,Aytu BioScience, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aytu BioScience, Inc.(AYTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aytu BioScience, Inc.(AYTU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction